• Home
  • About Us
    • About Us
    • Subscribe
    • Privacy Policy
  • Advertise
    • Advertise On IP Watch
    • Editorial Calendar
  • Videos
  • Links
  • Help

Intellectual Property Watch

Original news and analysis on international IP policy

  • Copyright
  • Patents
  • Trademarks
  • Opinions
  • People News
  • Venues
    • Bilateral/Regional Negotiations
    • ITU/ICANN
    • United Nations – other
    • WHO
    • WIPO
    • WTO/TRIPS
    • Africa
    • Asia/Pacific
    • Europe
    • Latin America/Caribbean
    • North America
  • Themes
    • Access to Knowledge/ Open Innovation & Science
    • Food Security/ Agriculture/ Genetic Resources
    • Finance
    • Health & IP
    • Human Rights
    • Internet Governance/ Digital Economy/ Cyberspace
    • Lobbying
    • Technical Cooperation/ Technology Transfer
  • Health Policy Watch

Industry Asks For Clarity On LDC Request To Extend TRIPS Pharma Waiver

01/05/2015 by Catherine Saez, Intellectual Property Watch Leave a Comment

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to email this to a friend (Opens in new window)
  • Click to print (Opens in new window)

Least developed countries (LDCs) at the World Trade Organization have requested that a waiver allowing them to not enforce intellectual property rights on pharmaceutical products be extended beyond its deadline of 1 January 2016. The brand pharmaceutical industry has published a statement that it supports access to medicines for LDCs but does not see the need for this extension as LDCs already benefit from a WTO waiver on all products until 2021.

This points to an inherent disagreement over whether the LDC pharmaceutical products extension is needed. In June 2013, WTO members in the Council for Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreed to extend a waiver allowing LDCs to defer their application of TRIPS provisions until 1 July 2021.

LDCs are also the beneficiaries of a separate waiver on pharmaceutical products, which comes to an end on 1 January 2016.

At the last TRIPS Council in February, Bangladesh on behalf of the LDCs requested an extension of the waiver on pharmaceutical products. For the moment both waivers run in parallel.

The difference is that LDCs asked for the pharmaceutical waiver to be extended until countries graduate from LDC status.

That request was also made for the general waiver but was not accepted by some developed countries (IPW, WTO/TRIPS, 25 February 2015).

The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) in the statement said it “firmly supports the efforts of governments and civil society to increase access to medicines in developing countries, particularly in LDCs.”

However, it said, “The vast majority of essential medicines are not protected by intellectual property (IP) and therefore IP plays no role in limiting access to these medicines.”

The IFPMA statement is available here.

The pharmaceutical industry supports the 2013 WTO decision to extend the waiver until 2021, and, according to the statement, “recognizes that LDCs may in due course need certain additional flexibility to implement TRIPS, [but] additional waivers or extensions do not appear to be necessary at this stage, as the current waiver is in force until 2021.”

The debate over the extension may be a moot point, however. Article 66 of the 1994 WTO TRIPS Agreement (Least-Developed Country Members) granted a 10 year exemption for LDCs, and specifies that “The Council for TRIPS shall, upon duly motivated request by a least-developed country Member, accord extensions of this period.”

 

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to email this to a friend (Opens in new window)
  • Click to print (Opens in new window)

Related

Catherine Saez may be reached at csaez@ip-watch.ch.

Creative Commons License"Industry Asks For Clarity On LDC Request To Extend TRIPS Pharma Waiver" by Intellectual Property Watch is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Filed Under: IP Policies, Language, Themes, Venues, Access to Knowledge/ Education, Development, Enforcement, English, Health & IP, Human Rights, Lobbying, Patents/Designs/Trade Secrets, Technical Cooperation/ Technology Transfer, Trademarks/Geographical Indications/Domains, WTO/TRIPS

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

  • Email
  • Facebook
  • LinkedIn
  • RSS
  • Twitter
  • Vimeo
My Tweets

IPW News Briefs

Saudis Seek Alternative Energy Partners Through WIPO Green Program

Chinese IP Officials Complete Study Of UK, European IP Law

Perspectives on the US

In US, No Remedies For Growing IP Infringements

US IP Law – Big Developments On The Horizon In 2019

More perspectives on the US...

Supported Series: Civil Society And TRIPS Flexibilities

Civil Society And TRIPS Flexibilities Series – Translations Now Available

The Myth Of IP Incentives For All Nations – Q&A With Carlos Correa

Read the TRIPS flexibilities series...

Paid Content

Interview With Peter Vanderheyden, CEO Of Article One Partners

More paid content...

IP Delegates in Geneva

  • IP Delegates in Geneva
  • Guide to Geneva-based Public Health and IP Organisations

All Story Categories

Other Languages

  • Français
  • Español
  • 中文
  • اللغة العربية

Archives

  • Archives
  • Monthly Reporter

Staff Access

  • Writers

Sign up for free news alerts

This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy

Copyright © 2022 · Global Policy Reporting

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.